Xtant Medical Holdings Inc

Xtant Medical Holdings Inc

XTNT · AMEX · Healthcare / Medical Devices

0.27USD-0.01 (-1.93%)

Price History

Full chart

Market Stats

Previous Close0.2753
Open0.31
Day Range0.26 – 0.31
52-Week Range0.27 – 0.95
Volume181.70K
Market Cap50.38M
P/E (TTM)0.00
Forward P/E34.84
EPS-0.08
Dividend Yield0.00%
Beta-0.15
50-Day Avg0.3726
200-Day Avg0.5108

About

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Sean E. Browne
  • Employees151
  • Headquarters664 Cruiser Lane, Belgrade, MT, United States, 59714, USA
  • Websitehttps://xtantmedical.com

Leadership

  • Mr. Sean E. BrownePresident, CEO & Director · b. 1966
  • Mr. Scott C. NeilsChief Financial Officer · b. 1985
  • Mr. Mark A. SchallenbergerChief Operations Officer · b. 1987
  • Ms. Catherine LundyVice President of Human Resources

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue459.23K7.39M15.42M30.15M32.98M33.07M35.33M59.35M90.00M82.61M72.20M64.68M53.34M55.26M57.97M91.30M117.27M133.93M
Growth (%)-+1509.98%+108.53%+95.55%+9.39%+0.28%+6.83%+67.97%+51.66%-8.21%-12.60%-10.42%-17.54%+3.61%+4.90%+57.50%+28.44%+14.21%
Cost of Revenue386.48K2.32M3.36M9.11M10.34M14.19M13.03M20.26M27.71M32.51M28.72M22.17M18.95M22.77M25.83M35.84M49.05M49.65M
Gross Profit72.75K5.08M12.05M21.04M22.64M18.89M22.30M39.08M62.29M50.10M43.49M42.52M34.39M32.49M32.14M55.47M68.22M84.27M
Gross Margin15.84%68.65%78.18%69.79%68.66%57.11%63.11%65.86%69.21%60.65%60.23%65.73%64.48%58.79%55.44%60.75%58.17%62.92%
Operating Expense88.59K8.70M20.67M27.49M27.59M27.90M28.56M51.16M69.84M87.94M103.56M44.87M35.14M36.34M38.89M65.63M80.29M76.99M
Operating Income-15.85K-3.62M-8.61M-6.45M-4.94M-9.01M-6.26M-12.08M-7.55M-37.83M-60.08M-2.35M-751.00K-3.85M-6.75M-10.16M-12.07M7.28M
Operating Margin-3.45%-49.00%-55.87%-21.39%-14.99%-27.24%-17.73%-20.35%-8.38%-45.80%-83.21%-3.64%-1.41%-6.97%-11.65%-11.13%-10.30%5.44%
EBITDA-15.85K-2.90M-17.14M-1.09M-5.07M-7.29M-3.90M-7.09M61.43K-29.31M-54.22M850.00K1.33M-2.51M-5.43M5.08M-7.88M15.89M
EBITDA Margin-3.45%-39.28%-111.15%-3.61%-15.36%-22.03%-11.02%-11.94%0.07%-35.48%-75.09%1.31%2.49%-4.55%-9.36%5.56%-6.72%11.87%
Net Income-15.85K-4.13M-19.47M-3.01M-7.71M-12.69M-10.51M-2.17M-19.49M-52.41M-70.10M-8.22M-7.02M-4.85M-8.48M660.00K-16.45M4.97M
Net Income Margin-3.45%-55.80%-126.27%-9.97%-23.39%-38.38%-29.74%-3.66%-21.66%-63.44%-97.09%-12.71%-13.17%-8.77%-14.64%0.72%-14.03%3.71%
R&D---00572.36K1.44M2.55M3.41M2.44M1.70M932.00K657.00K870.00K915.00K1.34M2.38M2.10M
R&D as % of Total Revenue---0.00%0.00%1.73%4.08%4.29%3.79%2.95%2.36%1.44%1.23%1.57%1.58%1.46%2.03%1.57%
Interest Expense0513.93K1.65M1.16M1.86M4.65M5.66M7.73M12.26M14.70M10.14M5.77M5.98M995.00K1.69M2.94M4.16M3.67M
Interest Expense % of Total Revenue0.00%6.95%10.69%3.86%5.65%14.07%16.02%13.03%13.62%17.80%14.05%8.92%11.20%1.80%2.92%3.22%3.55%2.74%

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets139.73K10.49M15.76M23.17M34.50M28.88M27.95M143.06M144.10M105.70M46.42M43.16M41.47M54.69M60.23M92.61M93.84M94.14M
Total Liabilities128.38K5.80M16.38M17.67M30.26M32.72M35.73M134.18M151.17M164.40M90.19M87.36M26.95M23.81M26.06M41.26M50.87M43.19M
Total Equity11.34K4.68M-619.24K5.50M4.23M-3.84M-7.77M8.88M-7.07M-58.70M-43.77M-44.20M14.51M30.88M34.17M51.35M42.96M50.95M
Cash43.72K54.16K327.48K751.11K4.93M3.05M4.47M6.37M2.58M2.86M6.80M5.24M2.34M18.24M20.30M5.71M6.20M17.05M
Total Debt-3.86M2.47M8.39M14.92M16.68M20.99M110.71M130.75M138.95M78.57M78.54M18.54M16.84M17.07M23.56M35.14M28.72M
Net Debt-43.72K3.80M2.14M7.64M10.00M13.63M16.53M104.34M128.17M136.10M71.77M73.30M16.20M-1.40M-3.23M17.84M28.94M11.66M

Cash Flow

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow38.64K-3.67M-8.37M-7.36M-10.79M-5.62M-7.32M-9.10M-14.41M-543.18K1.21M-413.00K-731.00K439.00K-5.34M-9.52M-11.90M12.55M
Investing Cash Flow-49.87K-816.37K-1.02M-1.84M35.32K-298.35K-73.57M-5.82M-1.61M-367.00K-544.00K-1.30M-1.89M-1.56M-24.78M-3.73M7.90M
Financing Cash Flow-3.44M9.46M8.80M16.80M3.71M9.04M84.57M16.43M2.43M3.10M-603.00K-861.00K17.50M9.02M19.69M16.07M-9.57M
Capital Expenditure093.67K816.37K1.10M1.84M693.30K299.98K2.26M5.83M1.64M624.00K879.00K1.54M2.12M1.76M1.46M4.11M2.38M
Free Cash Flow38.64K-3.77M-9.19M-8.46M-12.63M-6.31M-7.62M-11.36M-20.24M-2.18M588.00K-1.29M-2.28M-1.68M-7.11M-10.97M-16.01M10.16M
Dividends Paid---000000----201.00K----
FCF to OCF100.00%102.55%109.75%114.94%117.02%112.33%104.10%124.87%140.48%402.05%48.51%312.83%311.35%-381.78%133.03%115.30%134.57%81.01%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%0.00%0.00%-----11.99%----

Earnings

Report DateSep 30, 2010Mar 2, 2011Jun 1, 2011Aug 11, 2011Nov 10, 2011Mar 22, 2012May 3, 2012Aug 9, 2012Nov 7, 2012Mar 26, 2013May 9, 2013Aug 6, 2013Nov 7, 2013Mar 19, 2014May 6, 2014Aug 12, 2014Nov 5, 2014Mar 17, 2015May 5, 2015Aug 12, 2015Nov 11, 2015Mar 15, 2016May 4, 2016Aug 1, 2016Nov 7, 2016Mar 9, 2017May 9, 2017Aug 9, 2017Nov 21, 2017Mar 13, 2018May 8, 2018Aug 7, 2018Nov 14, 2018Dec 31, 2018May 15, 2019Aug 8, 2019Nov 7, 2019Mar 5, 2020May 7, 2020Aug 3, 2020Oct 29, 2020Feb 24, 2021May 11, 2021Aug 5, 2021Nov 12, 2021Mar 8, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 7, 2023May 4, 2023Aug 1, 2023Nov 9, 2023Feb 13, 2024Apr 1, 2024Aug 8, 2024Nov 12, 2024Mar 31, 2025May 12, 2025Aug 12, 2025Nov 10, 2025Mar 5, 2026May 13, 2026Aug 11, 2026Nov 9, 2026
EPS Estimate----7.20-1.20-4.08-5.10-5.40-4.32-4.08-4.50-3.60-5.70-8.80-4.80-5.84-3.60-4.20-3.60-3.60-3.48-2.64-4.86-4.32-3.84-2.64-3.54-1.20-0.48-3.49-0.38-0.27-0.19-0.32-0.36-0.52-0.28-0.21--0.11-0.11-0.12----0.03----0.02-0.03-0.02-0.01-0.02-0.02-0.02-0.02-0.02-0.01-0.02-0.01-0.01-0.02-0.02-
EPS Actual-30.66-18.1013.28-1.20-4.52-13.20-3.602.40-6.72-13.20-6.44-6.00-8.20-8.40-5.92-6.03-5.43-5.52-5.66-4.85-5.69-4.92-5.34-3.98-4.31-3.30-3.48-6.18-5.64-18.77-0.54-0.38-0.24-0.23-0.21-0.15-0.14-0.12-0.19-0.19-0.10-0.01-0.01-0.01-0.02-0.03-0.03-0.02-0.03-0.02-0.02-0.020.07-0.03-0.02-0.02-0.04-0.010.010.030.01-0.01-0.02-0.07-
Surprise---83.33%-276.67%-223.53%29.41%144.44%-55.56%-223.53%-43.11%-66.67%-43.86%4.55%-23.33%-3.25%-50.83%-31.43%-57.22%-34.72%-63.51%-86.36%-9.88%7.87%-12.24%-25.00%1.69%-415.00%-1075.00%-437.82%-42.11%-40.74%-26.32%28.13%41.67%71.15%50.00%42.86%--72.73%9.09%91.67%---0.00%---0.00%33.33%0.00%800.00%-50.00%0.00%0.00%-100.00%33.00%200.00%250.00%200.00%-182.00%0.00%-250.00%-
Timing---After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market---Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hours-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap50.38M
Enterprise Value68.75M
Trailing P/E0.00
Forward P/E34.84
PEG Ratio1.74
Price / Sales0.46
Price / Book1.31
EPS-0.08
Book Value0.285
Revenue (TTM)109.53M
Gross Profit (TTM)65.05M
EBITDA-1.47M
Profit Margin-10.17%
Operating Margin-18.10%
Return on Equity-25.16%
Return on Assets-3.75%
Shares Outstanding140.29M
Shares Float54.18M
Beta-0.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 1.03
  • Strong Buy
    2

Stock Splits

  • Feb 14, 20181:12
  • Jul 28, 20141:10